GlassScriptPhysician profile
Michael J Vazquez
NPI 1417548884
$1,077.77
in general payments reported to CMS, 2019-2025
15 companies · $582 in 2025
The $582 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $56.36 · 2023: $165 · 2024: $130 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $259.05 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $169.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $161.67 | 2021-2025 | |
| Lilly USA, LLC | $134.85 | 2023-2025 | Zepbound, Mounjaro |
| Currax Pharmaceuticals LLC | $57.83 | 2021-2023 | Onzetra Xsail, Contrave |
| Glaxosmithkline, LLC. | $54.67 | 2021-2023 | Trelegy Ellipta |
| Ibsa Pharma INC. | $42.09 | 2022-2025 | Tirosint, Flector, Licart |
| Astellas Pharma US INC | $34.35 | 2024 | Veozah |
| Gilead Sciences, INC. | $31.75 | 2025 | |
| Boston Scientific Corporation | $29.69 | 2025 | Farapulse |
| Dexcom, INC. | $24.88 | 2025 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $21.83 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.50 | 2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $20.49 | 2021 | |
| Eisai INC. | $15.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.